Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 11/2016

01-11-2016 | Review Paper

HPV Update: Vaccination, Screening, and Associated Disease

Authors: Megan McNamara, MD, MSc, Pelin Batur, MD, Judith M. E. Walsh, MD, MPH, Kay M. Johnson, MD, MPH

Published in: Journal of General Internal Medicine | Issue 11/2016

Login to get access

Abstract

Human papillomavirus (HPV) infection is the causative agent in cervical cancer, and is associated with numerous other genital cancers, including vulvar, vaginal, and anal cancer. Primary prevention with HPV vaccination is safe and efficacious, and a recently approved HPV vaccine will provide even more extensive protection against several oncogenic HPV strains. Screening strategies for HPV are rapidly evolving, reflecting the essential role that HPV infection plays in cervical cancer. This article highlights new evidence regarding the efficacy of the recently approved 9-valent HPV (9vHPV) vaccine and the use of primary high-risk HPV testing in cervical cancer screening. We consider the utility of urinary HPV testing in routine clinical practice and review current guidelines regarding anal HPV screening.
Literature
1.
Wu X, Watson M, Wilson R, Saraiya M, Cleveland JL, Markowitz L. Human papillomavirus–associated cancers—United States, 2004–2008. MMWR. 2012;61:41–5.
2.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626–1636.CrossRefPubMed
3.
Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2014;63(5):1–30.PubMed
4.
Thaxton L, Waxman AG. Cervical cancer prevention immunization and screening 2015. Med Clin N Am. 2015;99:469–477.CrossRefPubMed
5.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.CrossRef
6.
Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.CrossRefPubMed
7.
Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health. 2013;53:679–82.CrossRefPubMed
8.
Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.
9.
Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR. 2015;64(29):784–92.PubMedPubMedCentral
10.
Joura EA, Giuliano AR, Iversen OE. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.CrossRefPubMed
11.
Petrosky D, Bocchini JA, Hariri S. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. 2015;64(11):300–304.PubMedPubMedCentral
12.
Brisson M, Laprise JF, Chesson HW, Drolet M, Malagon T, Boily MC, et al. Health and economic impact of swithing from a 4-valent to a 9-valent HPV vaccination program in the United States. JNCI J Natl Cancer Inst. 2016;108(1): djv282. doi:10.​1093/​jnci/​djv282.
13.
14.
15.
Heirweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597–603.CrossRef
16.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;62:147–172.
17.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–197.CrossRefPubMed
18.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed
19.
Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125(2):330–7.CrossRefPubMed
20.
Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156: 880–91,W312.
21.
Committee on Practice Bulletins—Gynecology. ACOG practice bulletin number 131: screening for cervical cancer. Obstet Gynecol. 2012;120:1222–38.
22.
Sawaya GF, Kulasingam S, Denberg TD, Qaseem A, Clinical Guidelines Committee of the American College of Physicians. Cervical cancer screening in average-risk women: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2015;162(12):851–9.CrossRefPubMed
23.
Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ. 2000;163(5):503–8.PubMedPubMedCentral
24.
Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for cervical HPV: systematic review and meta-analysis. BMJ. 2014;349:g5264.
25.
Machalek DA, Poynten M, Jin F, Fairley CK, Fransworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13:487–500.CrossRefPubMed
26.
Steier EA, Sebring MC, Mendez AE, Ba FS, Trimble DD, Chiao EY. Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review. Am J Obstet Gynecol. 2015;213(3):278–309.CrossRef
27.
Shvestov YB, Hernandez BY, McDuffie K, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis. 2009;48:536–46.CrossRef
28.
Valari O, Koliopoulos G, Karakitsos P, et al. Human papillomavirus and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications. Gynecol Oncol. 2011;122:505–8.CrossRefPubMed
29.
Sehnal B, Dusek L, Cibula D, et al. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. J Clin Virol. 2014;59(1):18–23.CrossRefPubMed
30.
Smyczek P, Singh AE, Romanowski B. Anal intraepithelial neoplasia: review and recommendations for screening and management. Int J STD AIDS. 2013;24(11):843–851.CrossRefPubMed
31.
32.
Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12:1–17.CrossRefPubMed
33.
Metadata
Title
HPV Update: Vaccination, Screening, and Associated Disease
Authors
Megan McNamara, MD, MSc
Pelin Batur, MD
Judith M. E. Walsh, MD, MPH
Kay M. Johnson, MD, MPH
Publication date
01-11-2016
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 11/2016
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-016-3725-z

Other articles of this Issue 11/2016

Journal of General Internal Medicine 11/2016 Go to the issue

Letter to the Editor

Vitamin D: Ten Beliefs

Capsule Commentary

Capsule Commentary on Jacobs et al., Development and Validation of the Spanish-Numeracy Understanding in Medicine Instrument

Original Research

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System

Original Research

Receipt of Cancer Screening Is a Predictor of Life Expectancy

Original Research

The CareFirst Patient-Centered Medical Home Program: Cost and Utilization Effects in Its First Three Years

Editorial

How Can We Improve the Efficiency of Specialty Care?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits